Skip to main content

Volume 10 Supplement 1

de Senectute: Age and Health Forum

Antiangiogenic therapy

A brief look at AMD and developments which have completely subverted the therapeutic approach to patients affected by this disease.

New therapies available include: monoclonal antibody inhibitors of VEGF (Peptaganib, Bevacizumab, Ranibizumab) with the protocols currently in use and a brief reference to new anti-angiogenic therapies that include: decoy of VEGF receptor (VEGF Trap, Small Interfering RNA based therapies, Bevasiranib and AGN211745, Sirolimus) and the VEGF cascade of tyrosine kinase inhibitors (Vatalanib, Pazopanib, TG100801, TG101095, AG013958 and AL39324).

Author information

Affiliations

Authors

Corresponding author

Correspondence to T Avitabile.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Avitabile, T. Antiangiogenic therapy. BMC Geriatr 10, L4 (2010). https://doi.org/10.1186/1471-2318-10-S1-L4

Download citation

Keywords

  • Public Health
  • Monoclonal Antibody
  • Tyrosine
  • Tyrosine Kinase
  • Bevacizumab